The article names a history of pituitary tumors, severe carpal tunnel syndrome, uncontrolled diabetes, or malignancy as reasons to avoid growth hormone
All medications are sourced from pharmacies that provide Certificates of Analysis
A downward trend in the weekly average is what matters
What makes Ipamorelin unique: Mimics natural HGH release patterns more closely Doesn't significantly affect cortisol or prolactin (unlike some other GHRPs) Very clean side effect profile Often called the "gold standard" of HGH alternatives for safety Benefits relevant to menopause: Improved muscle mass and strength Reduced body fat, particularly abdominal Better bone density Enhanced sleep quality Improved cognitive function Better immune function Typical protocol: Dose: 200-300 mcg subcutaneously Timing: Before bed or in divided doses (morning and evening) Frequency: Daily Cycle length: 8-12 weeks on, 4 weeks off, or continuous at lower doses CJC-1295 CJC-1295 is another GHRH analog, often used in combination with Ipamorelin for synergistic effects
However, Phase 2 trials are not always powered or designed to detect rare psychiatric adverse events, and longer-term Phase 3 data which would provide a more comprehensive safety profile had not been fully published at the time of writing
Other GLP-1 and dual-agonist agents, including tirzepatide, are also in wide use, though not every GLP-1 on the market carries an FDA weight loss indication